Management of Elevated Testosterone Levels

Immediate Actions

The American College of Physicians recommends temporarily discontinuing testosterone therapy to allow levels to decrease in patients with elevated testosterone levels during hormone replacement therapy 1, 2
A comprehensive evaluation should be performed, including hematocrit/hemoglobin measurement to assess for erythrocytosis, PSA testing if male over 40, blood pressure measurement to check for hypertension, and assessment for fluid retention or edema 2, 3, 4, 5, 6, 7

Erythrocytosis is a common serious complication, especially with injectable testosterone formulations, with a risk increase of 17.9% incidence with higher doses 2, 7
The Endocrine Society notes that severely elevated testosterone levels pose risks of prostate-related complications, including potential exacerbation of benign prostatic hyperplasia and theoretical risk of unmasking occult prostate cancer 2, 6
Other risks include fluid retention, gynecomastia, and sleep apnea exacerbation 1, 2

The American Heart Association recommends considering therapeutic phlebotomy if hematocrit is significantly elevated (>54%) 4, 7
After testosterone levels normalize, resume therapy at a lower dose (typically 25-50% reduction) and consider switching from injectable to transdermal formulations 7
Monitor testosterone levels 1-2 months after restarting therapy and adjust dose to maintain testosterone in mid-normal range 4
Continue regular monitoring every 3-6 months for the first year, then annually 6

The American Urological Association notes that exogenous testosterone suppresses spermatogenesis through negative feedback on the hypothalamic-pituitary-gonadal axis, and alternative approaches should be considered if fertility is desired 8
Use testosterone with caution in patients with cardiac, renal, or hepatic disease due to risk of edema, and consider more frequent monitoring in patients with risk factors for cardiovascular disease 2, 7

Failure to recognize the urgency of severely elevated testosterone levels requires immediate intervention, not just routine follow-up 2
Inadequate monitoring after restarting therapy can lead to recurrence of supraphysiologic levels, and close monitoring is essential 4, 6
Ignoring fertility implications can have significant consequences, and young men should be counseled about potential fertility impacts before and during testosterone therapy 8
Overlooking formulation differences can lead to increased risk of erythrocytosis, and injectable testosterone is more likely to cause erythrocytosis than topical preparations 7